OncoMatch/Clinical Trials/NCT04999761
AB122 Platform Study
Is NCT04999761 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for advanced or metastatic solid tumor.
Treatment: AB122 · AB122 · TAS-116 · AB122 · TAS-116 · AB122 · TAS-116 · AB122 · TAS-120 · AB122 · TAS-115 · AB122 · TAS-115 · AB122 · TAS-102 · Ramucirumab · AB122 · TAS-102 · Bevacizumab · AB122 · AB122 · TAS-120 · Fluorouracil · Cisplatin · AB122 · TAS-120 · AB154 · AB122 · TAS-120 · Fluorouracil · Carboplatin · Cisplatin · AB122 · TAS-120 · AB154 · AB122 · TAS-120 · Carboplatin · nab-Paclitaxel · AB122 · TAS-120 · Cisplatin · Gemcitabine · AB122 · TAS-120 · nab-Paclitaxel · Gemcitabine — This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Pancreatic Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Gastric Cancer
Sarcoma
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Cholangiocarcinoma
Biomarker criteria
Required: KRAS wild type
Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type
Required: NRAS wild type
Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type
Required: PD-L1 (CD274) ≥ 50% tumor proportion score (≥ 50% TPS)
Has PD-L1 (≥ 50% tumor proportion score) in tumor tissue sample as determined at a local laboratory
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Exception: except for cohort B-3, C-1, D-1 tolerability part and E-1
Prior treatment with an anti-PD-L1 anti-PD-1, anti-CTLA-4, or other ICI or agonist as monotherapy or in combination (except for cohort B-3, C-1, D-1 tolerability part and E-1)
Lab requirements
Blood counts
ANC ≥ 1500 /mm3; Platelet count ≥ 100000 /mm3; Hemoglobin value of ≥ 9.0 g/dL
Liver function
AST and ALT ≤ 3 × ULN; or if a patient with documented liver metastases, AST and ALT ≤ 5 × ULN; T-Bil of ≤ 1.5 × ULN
AST and ALT ≤ 3 × ULN; or if a patient with documented liver metastases, AST and ALT ≤ 5 × ULN; T-Bil of ≤ 1.5 × ULN; ANC ≥ 1500 /mm3; Platelet count ≥ 100000 /mm3; Hemoglobin value of ≥ 9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04999761 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS wild type is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS wild type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 ≥ 50% tumor proportion score is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify